Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard cancer health scale (called ECOG status 0, 1, or 2)
- People who have been formally diagnosed with symptomatic Multiple Myeloma (MM) according to recognised international diagnostic guidelines
- People whose myeloma can be measured and tracked to assess how it responds to treatment, based on standard international criteria
- People who have not yet received any treatment for Multiple Myeloma, except for emergency or pain-relief radiation therapy, or up to one month of a single steroid medication (with appropriate time since last dose as set out in the protocol)
- People whose bone marrow, liver, kidneys, and heart are functioning at an adequate level as defined in the study protocol
- People who are under 70 years of age and whose liver, kidney, lung, and heart function meet the standards required to be considered suitable for a stem cell transplant, based on their treating institution's guidelines
Who may not be able to join:
- People who are currently taking another experimental treatment known or suspected to work against Multiple Myeloma, or any treatment targeting a specific set of proteins involved in myeloma cell survival (the APRIL/TACI/BCMA pathway)
- People who have Multiple Myeloma that has spread to the brain or central nervous system, a known or suspected brain condition called Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive or movement disorders affecting the brain or nervous system, or a seizure within the 12 months before enrolling in the study
- People whose disease is progressing rapidly and urgently — for example, with worsening kidney failure or high calcium levels that are not responding to standard treatments — and who need chemotherapy right away
- People diagnosed with certain related but distinct blood or plasma cell conditions, including non-secretory myeloma, active plasma cell leukaemia, primary light-chain (AL) amyloidosis, Waldenström macroglobulinaemia, or POEMS syndrome
Note: Additional eligibility criteria beyond those listed here are described in the full study protocol. The trial site will assess all criteria in detail.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Dose-Limiting Toxicities (DLTs); Incidence of Treatment-Emergent Adverse Events (TEAEs); Severity of TEAEs; Incidence of Adverse Events of Special Interest (AESIs); Severity of AESIs; Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria; Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy; Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy;...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.